<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TETRACOSACTIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TETRACOSACTIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#effectOnLaboratoryTests" data-toggle="tab">Effect on laboratory tests</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diagnosis of adrenocortical insufficiency (diagnostic 30-minute test)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250 micrograms for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diagnosis of adrenocortical insufficiency (diagnostic 5-hour test)</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection using depot injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 mg for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Alternative to corticosteroids in conditions such as Crohn's disease or rheumatoid arthritis (formerly used but value was limited by the variable and unpredictable therapeutic response and by the waning of effect with time)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intramuscular injection using depot injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1 mg daily, alternatively (by intramuscular injection) initially 1 mg every 12 hours, (in acute cases), then (by intramuscular injection) reduced to 1 mg every 2&#8211;3 days, followed by (by intramuscular injection) 1 mg once weekly, alternatively (by intramuscular injection) 500 micrograms every 2&#8211;3 days.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid (but may be used diagnostically if essential).</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>An enhanced effect of tetracosactide therapy may occur in patients with cirrhosis of the liver.</p><p>Use with caution in hepatic impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution in patients with renal impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Acute psychosis</li>
            <li>adrenogenital syndrome</li>
            <li>allergic disorders</li>
            <li>asthma</li>
            <li>avoid injections containing benzyl alcohol in neonates</li>
            <li>Cushing's syndrome</li>
            <li>infectious diseases</li>
            <li>peptic ulcer</li>
            <li>primary adrenocortical insufficiency</li>
            <li>refractory heart failure</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Abdominal distention, abscess, acne, anaphylactic shock, angioneurotic oedema, aseptic necrosis of femoral and humeral heads, benign intracranial pressure increased with papilloedema, calcium deficiency, cardiac disorders, convulsions, Cushing's syndrome, decreased carbohydrate tolerance, dizziness, dysponea, ecchymosis, erythema, euphoria, fluid retention, flushing, glaucoma, growth retardation, headache, hirsutism, hyperglycaemia, hyperhidrosis, hypersensitivity reactions (tend to be more severe in patients susceptible to allergies, especially asthma), hypertension, hypokalaemia, hypokalaemic alkalosis, impaired healing, increased appetite, increased intraocular pressure, infection susceptibility increased, insomnia, irregular menstruation, leukocytosis, malaise, manifestations of latent diabetes mellitus, mood swings, muscle atrophy, muscular weakness, myopathy, nausea, necrotising vasculitis, negative nitrogen balance, osteoporosis, pancreatitis, pathological fracture of long bones, peptic ulcer, personality changes, petechiae, posterior subcapsular cataracts, pruritis, psychotic manifestations, Quincke's oedema, secondary adrenocortical unresponsiveness, secondary pituitary unresponsiveness, severe depression, skin atrophy, skin hyperpigmentation, skin reactions at injection site, sodium retention, spinal compression fractures, tendon rupture, thromboembolism, ulcerative oesophagitis, urticaria, vertigo, vomiting, weight increase,
              </p>
        
        
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active infectious diseases (should not be used unless adequate disease-specific therapy is being given)
          </li>
          <li>
            active systemic diseases (should not be used unless adequate disease-specific therapy is being given)
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
            diverticulitis
          </li>
          <li>
            history of asthma
          </li>
          <li>
            history of atopic allergy
          </li>
          <li>
            history of eczema
          </li>
          <li>
            history of hayfever
          </li>
          <li>
            history of hypersensitivity
          </li>
          <li>
            hypertension
          </li>
          <li>
            latent amoebiasis (may become activated)
          </li>
          <li>
            latent tuberculosis (may become activated)
          </li>
          <li>
            myasthenia gravis
          </li>
          <li>
            ocular herpes simplex
          </li>
          <li>
            osteoporosis
          </li>
          <li>
            predisposition to thromboembolic
          </li>
          <li>
            pscyhological disturbances may be triggered
          </li>
          <li>
            recent intestinal anastomosis
          </li>
          <li>
            reduced immune response (should not be used unless adequate disease-specific therapy is being given)
          </li>
          <li>
            ulcerative colitis
          </li>
        </ul>
        <ul>
          <li>
            <p>Should only be administered under medical supervision.</p><p>Consult product literature.</p>
          </li>
          <li>
            <p>Patients already receiving medication for moderate to severe hypertension must have their dosage adjusted if treatment started.</p>
          </li>
          <li>
            <p>Patients already receiving medication for diabetes mellitus must have their dosage adjusted if treatment started.</p>
          </li>
        </ul>
      </section>









      <section class="tab-pane" id="effectOnLaboratoryTests">
        <h2>Effect on laboratory tests</h2>

            <section class="effectOnLaboratoryTests">
              <p>May suppress skin test reactions.</p>
            </section>
            <section class="effectOnLaboratoryTests">
              <p>Post administration total plasma cortisol levels during 30-minute test for diagnosis of adrenocotical insufficiency might be misleading due to altered cortisol binding globulin levels in some special clinical situations including, patients on oral contraceptives, post-operative patients, critical illness, severe liver disease and nephrotic syndrome.</p>
            </section>
      </section>



      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated in patients with history of hypersensitivity to tetracosactide/corticotrophins or excipients.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TETRACOSACTIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75243"><a href="../medicinalForm/PHP75243.html" data-target="#PHP75243" data-action="load">Solution for injection</a></div>
            <div id="PHP75237"><a href="../medicinalForm/PHP75237.html" data-target="#PHP75237" data-action="load">Suspension for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
